IS5280A - Samsetningar til meðhöndlunar og fyrirbyggingar ásegamyndun í slagæð og notkun á þætti Xa lata einum sér og/eða í samsetningu með miðli gegn blóðflöguþyrpingu - Google Patents

Samsetningar til meðhöndlunar og fyrirbyggingar ásegamyndun í slagæð og notkun á þætti Xa lata einum sér og/eða í samsetningu með miðli gegn blóðflöguþyrpingu

Info

Publication number
IS5280A
IS5280A IS5280A IS5280A IS5280A IS 5280 A IS5280 A IS 5280A IS 5280 A IS5280 A IS 5280A IS 5280 A IS5280 A IS 5280A IS 5280 A IS5280 A IS 5280A
Authority
IS
Iceland
Prior art keywords
lata
prevention
alone
compositions
treatment
Prior art date
Application number
IS5280A
Other languages
English (en)
Other versions
IS2619B (is
Inventor
Bernat André
Herbert Jean-Marc
Petitou Maurice
Van Amsterdam Ronald
Original Assignee
Sanofi- Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi- Aventis filed Critical Sanofi- Aventis
Publication of IS5280A publication Critical patent/IS5280A/is
Publication of IS2619B publication Critical patent/IS2619B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS5280A 1997-06-13 1999-11-30 Notkun á fásykruhindra á þátt Xa í blöndu með storkuvarnar miðli til að meðhöndla slagæðasegarek. IS2619B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9707368A FR2764511B1 (fr) 1997-06-13 1997-06-13 Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
PCT/FR1998/001172 WO1998056365A1 (fr) 1997-06-13 1998-06-09 INHIBITEUR DU FACTEUR Xa SEUL OU EN COMBINAISON AVEC UN ANTIAGREGANT PLAQUETTAIRE, CONTRE LA THROMBOSE ARTERIELLE

Publications (2)

Publication Number Publication Date
IS5280A true IS5280A (is) 1999-11-30
IS2619B IS2619B (is) 2010-05-15

Family

ID=9507960

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5280A IS2619B (is) 1997-06-13 1999-11-30 Notkun á fásykruhindra á þátt Xa í blöndu með storkuvarnar miðli til að meðhöndla slagæðasegarek.

Country Status (42)

Country Link
US (2) US6541488B1 (is)
EP (1) EP0986376B1 (is)
JP (1) JP3988803B2 (is)
KR (1) KR100598451B1 (is)
CN (1) CN1253150C (is)
AR (1) AR012247A1 (is)
AT (1) ATE384528T1 (is)
AU (1) AU728826B2 (is)
BR (1) BR9810520A (is)
CA (1) CA2293415C (is)
CO (1) CO4940476A1 (is)
CY (1) CY1107912T1 (is)
CZ (1) CZ299518B6 (is)
DE (1) DE69839046T2 (is)
DK (1) DK0986376T3 (is)
DZ (1) DZ2512A1 (is)
EE (1) EE04737B1 (is)
ES (1) ES2299209T3 (is)
FR (1) FR2764511B1 (is)
GT (1) GT199800171A (is)
HR (1) HRP980322B1 (is)
HU (1) HU227956B1 (is)
ID (1) ID29309A (is)
IL (1) IL133452A (is)
IS (1) IS2619B (is)
ME (1) ME00685B (is)
MY (1) MY124648A (is)
NO (1) NO323739B1 (is)
NZ (1) NZ501452A (is)
PL (1) PL193405B1 (is)
PT (1) PT986376E (is)
RS (1) RS49902B (is)
RU (1) RU2212886C2 (is)
SA (1) SA98190552B1 (is)
SI (1) SI0986376T1 (is)
SK (1) SK286311B6 (is)
TR (1) TR199903087T2 (is)
TW (1) TW565442B (is)
UA (1) UA70919C2 (is)
UY (1) UY25044A1 (is)
WO (1) WO1998056365A1 (is)
ZA (1) ZA985137B (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
FR2793687B1 (fr) * 1999-04-26 2001-08-24 Sanofi Sa Nouvelle composition injectable d'un anticoagulant
FR2800074B1 (fr) * 1999-10-22 2001-12-21 Aventis Pharma Sa Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US6756208B2 (en) 2001-02-28 2004-06-29 John H. Griffin Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C
UA80399C2 (en) * 2001-11-13 2007-09-25 Glaxo Group Ltd Use of specific dose of fondaparinux sodium for the treatment of acs
US20040067995A1 (en) 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
US20070004736A1 (en) * 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
RU2245162C2 (ru) * 2003-01-04 2005-01-27 Козлов Владимир Александрович Способ терапии инфаркта миокарда
JP4855073B2 (ja) * 2003-09-19 2012-01-18 キッセイ薬品工業株式会社 併用医薬
WO2005087266A1 (en) * 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
WO2005104552A1 (ja) * 2004-04-23 2005-11-03 Sumitomo Electric Industries, Ltd. 動画像データの符号化方法、復号化方法、これらを実行する端末装置、及び双方向対話型システム
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
JP5557410B2 (ja) * 2004-07-13 2014-07-23 第一三共株式会社 経口投与による血栓・塞栓の予防治療剤
US20070105825A1 (en) * 2004-09-16 2007-05-10 Yuji Hoyano Concurrent drugs
US20090111769A1 (en) * 2005-10-10 2009-04-30 De Kort Martin Antithrombotic Compound
WO2010029552A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
RU2410104C1 (ru) * 2009-07-10 2011-01-27 Учреждение Российской академии медицинских наук Научный центр неврологии РАМН СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
KR101968190B1 (ko) * 2014-10-30 2019-04-11 청두 바이위 파머수티컬 씨오., 엘티디 징코라이드 B(Ginkgolide B)와 Ⅹa 인자 억제제를 포함한 약물 조성물 및 그 제조방법과 용도
CN106860868B (zh) * 2015-12-11 2019-11-22 北京百奥药业有限责任公司 沙班类药物与蚓激酶的药物组合物、制剂及其应用
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE419871B (sv) * 1975-12-01 1981-08-31 Pharmacia Ab Sett att bestemma aktiviteten hos faktor xa-inhibitor i blod
DE3038163A1 (de) * 1980-10-09 1982-05-06 Boehringer Mannheim Gmbh, 6800 Mannheim Thrombininhibitor, seine herstellung und verwendung
FR2548189B1 (fr) * 1983-07-01 1986-04-11 Choay Sa Nouveaux produits contenant des oligosaccharides, leur preparation et leurs applications biologiques et biochimiques
RU2045264C1 (ru) * 1983-12-15 1995-10-10 Белорусский научно-исследовательский институт кардиологии Антиагрегационное средство
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
FR2728901B1 (fr) * 1994-12-28 1997-03-28 Sanofi Sa Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
SI0946185T2 (sl) 1996-11-27 2010-08-31 Aventis Pharma Inc Farmacevtski sestavek, ki obsega spojino z anti-Xa-aktivnostjo in antagonistično spojino za agregacijo ploščic
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire

Also Published As

Publication number Publication date
IS2619B (is) 2010-05-15
ATE384528T1 (de) 2008-02-15
EE04737B1 (et) 2006-12-15
DK0986376T3 (da) 2008-05-13
PT986376E (pt) 2008-04-01
HRP980322B1 (en) 2003-12-31
HUP0002175A3 (en) 2003-05-28
FR2764511B1 (fr) 2000-09-08
UY25044A1 (es) 2000-10-31
NO996137L (no) 2000-02-14
KR20010013690A (ko) 2001-02-26
ES2299209T3 (es) 2008-05-16
US20040092477A1 (en) 2004-05-13
JP3988803B2 (ja) 2007-10-10
PL193405B1 (pl) 2007-02-28
CY1107912T1 (el) 2013-09-04
AU728826B2 (en) 2001-01-18
DZ2512A1 (fr) 2003-02-01
HK1032750A1 (en) 2001-08-03
CA2293415A1 (en) 1998-12-17
JP2002504110A (ja) 2002-02-05
FR2764511A1 (fr) 1998-12-18
KR100598451B1 (ko) 2006-07-10
WO1998056365A1 (fr) 1998-12-17
AU7924698A (en) 1998-12-30
DE69839046T2 (de) 2009-01-15
CO4940476A1 (es) 2000-07-24
CN1253150C (zh) 2006-04-26
DE69839046D1 (de) 2008-03-13
TW565442B (en) 2003-12-11
AR012247A1 (es) 2000-09-27
ID29309A (id) 2001-08-16
CZ446099A3 (cs) 2000-04-12
ME00685B (me) 2008-08-07
SK286311B6 (en) 2008-07-07
SA98190552B1 (ar) 2006-09-09
HUP0002175A1 (hu) 2000-11-28
GT199800171A (es) 2000-04-21
RU2212886C2 (ru) 2003-09-27
EP0986376A1 (fr) 2000-03-22
EE9900574A (et) 2000-08-15
YU63699A (sh) 2002-06-19
CZ299518B6 (cs) 2008-08-20
TR199903087T2 (xx) 2000-05-22
CA2293415C (en) 2011-08-09
RS49902B (sr) 2008-08-07
ZA985137B (en) 1999-01-07
BR9810520A (pt) 2000-09-19
MY124648A (en) 2006-06-30
NZ501452A (en) 2002-06-28
NO323739B1 (no) 2007-07-02
HU227956B1 (en) 2012-07-30
IL133452A0 (en) 2001-04-30
SK170999A3 (en) 2000-07-11
EP0986376B1 (fr) 2008-01-23
CN1274281A (zh) 2000-11-22
US6541488B1 (en) 2003-04-01
SI0986376T1 (sl) 2008-06-30
UA70919C2 (uk) 2004-11-15
IL133452A (en) 2004-09-27
NO996137D0 (no) 1999-12-10
PL337288A1 (en) 2000-08-14
HRP980322A2 (en) 1999-04-30

Similar Documents

Publication Publication Date Title
DK1087778T3 (da) Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
DE69911786D1 (de) Luftgetriebene pumpen und ihre bauteile
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
EE04737B1 (et) Kompositsioonid arteriaalse tromboosi ärahoidmiseks ja raviks ning Xa faktori inhibiitori kasutamine iseseisvalt ja/või kombineeritult vereliistakuteagregeerumise vastase toimeainega
NO20032753D0 (no) Forbindelse og anvendelse derav
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
NO20006488D0 (no) Sammensetning og anvendelse
DK1212317T3 (da) Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser
DE69839392D1 (de) In 1-stellung substituierte 4-carbamoyl-1,2,4-triazol-5-on-derivate und herbizide
HUP0103845A3 (en) Disinfecting composition and its use
DE69906754D1 (de) Einbringung von rauchmodifizierenden mitteln in rauchartikeln
NO20004274L (no) Proteaseaktivert reseptor 4 og anvendelse derav
DK0898566T3 (da) Substituerede benzylaminer og anvendelse deraf til behandling af depression
NO986174L (no) Triazinderivater og anvendelse derav
DK1084251T3 (da) Svækkede pestivira
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
IL131085A0 (en) The use of levobupivacaine or ropivacaine in treating migraine
NO20006626D0 (no) Beleggingsmiddel og anvendelse herav
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
DE69534555D1 (de) Füllen von Löchern und Ähnlichem in Substraten
NO995560D0 (no) Reologi omforming og omformingsmidler
FI964809A0 (fi) En utrustning foer tillverkning av taeckplaot
FI964316A0 (fi) Vesi- ja kemikaalikiertokulku